233 related articles for article (PubMed ID: 36243280)
21. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
Dilworth TJ; Ibrahim OM; Mercier RC
J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
[TBL] [Abstract][Full Text] [Related]
22. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
[TBL] [Abstract][Full Text] [Related]
23. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
24. Reduction of
Honda N; Tagashira Y; Kawai S; Kobayashi T; Yamamoto M; Shimada K; Yokogawa N
Scand J Rheumatol; 2021 Sep; 50(5):365-371. PubMed ID: 33749507
[No Abstract] [Full Text] [Related]
25. Sub-therapeutic trimethoprim and sulfamethoxazole plasma concentrations during continuous venovenous hemofiltration in a patient with COVID-19 and pulmonary
le Noble JLML; Foudraine N; van der Elst KCM; Bouwman S
Int J Clin Pharmacol Ther; 2023 Nov; 61(11):525-530. PubMed ID: 37489071
[TBL] [Abstract][Full Text] [Related]
26. Alternative pneumocystis prophylaxis in solid organ transplant recipients at two large transplant centers.
Lum J; Echenique I; Athans V; Koval CE
Transpl Infect Dis; 2021 Feb; 23(1):e13461. PubMed ID: 32894607
[TBL] [Abstract][Full Text] [Related]
27. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
28. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
Geerlinks AV; Campigotto A; Science M; Gupta S
Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
[TBL] [Abstract][Full Text] [Related]
29. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
[TBL] [Abstract][Full Text] [Related]
30. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation.
Lu YM; Lee YT; Chang HC; Yang HS; Chang CY; Huang CM; Wei J
Transplant Proc; 2017 Oct; 49(8):1893-1898. PubMed ID: 28923644
[TBL] [Abstract][Full Text] [Related]
31. Application of Metagenomic Next-Generation Sequencing to Diagnose Pneumocystis jirovecii Pneumonia in Kidney Transplantation Recipients.
Xu J; Yu Y; Lv J; Yang S; Wu J; Chen J; Peng W
Ann Transplant; 2021 Jun; 26():e931059. PubMed ID: 34099614
[TBL] [Abstract][Full Text] [Related]
32. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
[TBL] [Abstract][Full Text] [Related]
33. Lifelong, universal Pneumocystis jirovecii pneumonia prophylaxis: Patient uptake and adherence after kidney transplant.
Peterson K; Berrigan L; Popovic K; Wiebe C; Sun S; Ho J
Transpl Infect Dis; 2021 Jun; 23(3):e13509. PubMed ID: 33171008
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
[TBL] [Abstract][Full Text] [Related]
35. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience.
Borstnar S; Lindic J; Tomazic J; Kandus A; Pikelj A; Prah J; Skvarc M; Godnov U; Kovac D
Transplant Proc; 2013 May; 45(4):1614-7. PubMed ID: 23726632
[TBL] [Abstract][Full Text] [Related]
36. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
37. Low-dose trimethoprim-sulfamethoxazole for the treatment of
Sohani ZN; Butler-Laporte G; Aw A; Belga S; Benedetti A; Carignan A; Cheng MP; Coburn B; Costiniuk CT; Ezer N; Gregson D; Johnson A; Khwaja K; Lawandi A; Leung V; Lother S; MacFadden D; McGuinty M; Parkes L; Qureshi S; Roy V; Rush B; Schwartz I; So M; Somayaji R; Tan D; Trinh E; Lee TC; McDonald EG
BMJ Open; 2022 Jul; 12(7):e053039. PubMed ID: 35863836
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
[TBL] [Abstract][Full Text] [Related]
39. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
40. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
